Table 1.
1) Baseline symptoms evaluation | Recommended |
2) EUS-FNAB | Recommended |
3) EUS-FNAC | Recommended |
4) Ultrasound imaging | Recommended |
5) Contrast-enhanced magnetic resonance imaging | Recommended |
6) Contrast-enhanced computed tomography | Recommended |
7) Positron emission tomography | Recommended only in metastatic setting |
8) Immunochemistry (CK, p63, GATA3, androgen receptor) | Recommended |
9) Radical parotidectomy en block with infiltrated structures modified Radical Neck dissection (level Ib-V) | Recommended in parotid gland carcinoma |
10) Sialoadenectomy en block with infiltrated structures Modified radical neck dissection (livel I-V) | Recommended in sub-mandibular carcinoma |
11) Adjuvant radiotherapy +/- concomitant chemotherapy (IMRT) | Recommended (in case of T3-T4, high grade, close/positive margin, perineural invasion, Nodal status positive, ENE+) |
12) Neoadjuvant chemotherapy | Not recommended TPF schedule Considered Carboplatin-Paclitaxel schedule |
13) Molecular profiling in metastatic setting:EGFR expression, RAS mutation, PDL1 expression, NOTCH mutation | Recommended for personalized therapy |
EUS-FNAB: endoscopic ultrasound guided-fine needle aspiration biopsy; EUS-FNAC: endoscopic ultrasound guided-fine needle aspiration cytology; ENE: extranodal extension.